세계의 알부민(부형제) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Albumin (as Excipient) was estimated to be worth US$ 1594 million in 2024 and is forecast to a readjusted size of US$ 2454 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Albumin (as Excipient) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Albumin excipients refer to human serum albumin (HSA) or recombinant human serum albumin (rHSA) used as excipients in biopharmaceuticals. Their primary functions include stabilizing the structure and activity of protein drugs, enhancing drug solubility and bioavailability as carriers, and serving as nutritional components in vaccines and cell culture media. With the advancement of biologics and vaccine development, the application of albumin excipients in drug formulations is becoming increasingly widespread.In 2024, global Albumin (as Excipient) production reached approximately 440 mt, with an average global market price of around US$ 3622 per kg.

The albumin excipient market is experiencing unprecedented growth opportunities due to the global rise in chronic diseases, rapid expansion of the biopharmaceutical industry, and increasing demand for efficient drug delivery systems. Particularly in vaccine development and gene therapy, albumin excipients have become indispensable components due to their excellent biocompatibility and stability. Furthermore, advancements in recombinant albumin technologies have made the production process safer and more controllable, further driving market growth.

Despite the promising prospects, the albumin excipient market faces several challenges. Firstly, the source and quality control of raw materials are critical, especially the supply of human-derived albumin, which may affect production stability. Secondly, stringent regulatory requirements and quality standards make the research and development process complex and time-consuming. Additionally, increasing market competition from emerging enterprises and technologies may threaten the market share of existing companies.

Downstream demand is primarily concentrated in areas such as vaccines, cell culture media, protein drugs, and gene therapies. With the rise of personalized medicine and precision therapy, the demand for high-quality excipients continues to increase. Moreover, the growing aging population globally is driving the demand for chronic disease treatment drugs, thereby boosting the need for albumin excipients.

The main raw materials for albumin excipients include human serum albumin and recombinant bovine serum albumin. Human serum albumin is primarily sourced from plasma collection; however, its supply is limited by the number of blood donors and ethical issues related to plasma collection. On the other hand, recombinant bovine serum albumin production relies on bioreactor technology, which has higher production costs and technical requirements. Therefore, the stable supply and cost control of raw materials are key factors influencing the development of the albumin excipient market.

This report aims to provide a comprehensive presentation of the global market for Albumin (as Excipient), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Albumin (as Excipient) by region & country, by Type, and by Application.

The Albumin (as Excipient) market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Albumin (as Excipient).

Market Segmentation

By Company

• CSL
• Grifols
• Takeda
• Octapharma
• Hualan Bio
• CBPO
• Shanghai RAAS
• Kedrion
• LFB Group
• Tiantan Bio
• Pailin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio

Segment by Type

• 20-25% Concentrations
• 5% Concentrations

Segment by Application

• Cell Culture Media
• Medical Excipient

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Albumin (as Excipient) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Albumin (as Excipient) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Albumin (as Excipient) in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Albumin (as Excipient) Product Introduction
• 1.2 Global Albumin (as Excipient) Market Size Forecast
  • 1.2.1 Global Albumin (as Excipient) Sales Value (2020-2031)
  • 1.2.2 Global Albumin (as Excipient) Sales Volume (2020-2031)
  • 1.2.3 Global Albumin (as Excipient) Sales Price (2020-2031)
• 1.3 Albumin (as Excipient) Market Trends & Drivers
  • 1.3.1 Albumin (as Excipient) Industry Trends
  • 1.3.2 Albumin (as Excipient) Market Drivers & Opportunity
  • 1.3.3 Albumin (as Excipient) Market Challenges
  • 1.3.4 Albumin (as Excipient) Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Albumin (as Excipient) Players Revenue Ranking (2024)
• 2.2 Global Albumin (as Excipient) Revenue by Company (2020-2025)
• 2.3 Global Albumin (as Excipient) Players Sales Volume Ranking (2024)
• 2.4 Global Albumin (as Excipient) Sales Volume by Company Players (2020-2025)
• 2.5 Global Albumin (as Excipient) Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Albumin (as Excipient) Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Albumin (as Excipient) Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Albumin (as Excipient)
• 2.9 Albumin (as Excipient) Market Competitive Analysis
  • 2.9.1 Albumin (as Excipient) Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Albumin (as Excipient) Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Albumin (as Excipient) as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 20-25% Concentrations
  • 3.1.2 5% Concentrations
• 3.2 Global Albumin (as Excipient) Sales Value by Type
  • 3.2.1 Global Albumin (as Excipient) Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Albumin (as Excipient) Sales Value, by Type (2020-2031)
  • 3.2.3 Global Albumin (as Excipient) Sales Value, by Type (%) (2020-2031)
• 3.3 Global Albumin (as Excipient) Sales Volume by Type
  • 3.3.1 Global Albumin (as Excipient) Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Albumin (as Excipient) Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Albumin (as Excipient) Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Albumin (as Excipient) Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Cell Culture Media
  • 4.1.2 Medical Excipient
• 4.2 Global Albumin (as Excipient) Sales Value by Application
  • 4.2.1 Global Albumin (as Excipient) Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Albumin (as Excipient) Sales Value, by Application (2020-2031)
  • 4.2.3 Global Albumin (as Excipient) Sales Value, by Application (%) (2020-2031)
• 4.3 Global Albumin (as Excipient) Sales Volume by Application
  • 4.3.1 Global Albumin (as Excipient) Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Albumin (as Excipient) Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Albumin (as Excipient) Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Albumin (as Excipient) Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Albumin (as Excipient) Sales Value by Region
  • 5.1.1 Global Albumin (as Excipient) Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Albumin (as Excipient) Sales Value by Region (2020-2025)
  • 5.1.3 Global Albumin (as Excipient) Sales Value by Region (2026-2031)
  • 5.1.4 Global Albumin (as Excipient) Sales Value by Region (%), (2020-2031)
• 5.2 Global Albumin (as Excipient) Sales Volume by Region
  • 5.2.1 Global Albumin (as Excipient) Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Albumin (as Excipient) Sales Volume by Region (2020-2025)
  • 5.2.3 Global Albumin (as Excipient) Sales Volume by Region (2026-2031)
  • 5.2.4 Global Albumin (as Excipient) Sales Volume by Region (%), (2020-2031)
• 5.3 Global Albumin (as Excipient) Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Albumin (as Excipient) Sales Value, 2020-2031
  • 5.4.2 North America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Albumin (as Excipient) Sales Value, 2020-2031
  • 5.5.2 Europe Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Albumin (as Excipient) Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Albumin (as Excipient) Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Albumin (as Excipient) Sales Value, 2020-2031
  • 5.7.2 South America Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Albumin (as Excipient) Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Albumin (as Excipient) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Albumin (as Excipient) Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Albumin (as Excipient) Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Albumin (as Excipient) Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Albumin (as Excipient) Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Albumin (as Excipient) Sales Value, 2020-2031
  • 6.3.2 United States Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Albumin (as Excipient) Sales Value, 2020-2031
  • 6.4.2 Europe Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Albumin (as Excipient) Sales Value, 2020-2031
  • 6.5.2 China Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Albumin (as Excipient) Sales Value, 2020-2031
  • 6.6.2 Japan Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Albumin (as Excipient) Sales Value, 2020-2031
  • 6.7.2 South Korea Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Albumin (as Excipient) Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Albumin (as Excipient) Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Albumin (as Excipient) Sales Value, 2020-2031
  • 6.9.2 India Albumin (as Excipient) Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Albumin (as Excipient) Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 CSL
  • 7.1.1 CSL Company Information
  • 7.1.2 CSL Introduction and Business Overview
  • 7.1.3 CSL Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 CSL Albumin (as Excipient) Product Offerings
  • 7.1.5 CSL Recent Development
• 7.2 Grifols
  • 7.2.1 Grifols Company Information
  • 7.2.2 Grifols Introduction and Business Overview
  • 7.2.3 Grifols Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Grifols Albumin (as Excipient) Product Offerings
  • 7.2.5 Grifols Recent Development
• 7.3 Takeda
  • 7.3.1 Takeda Company Information
  • 7.3.2 Takeda Introduction and Business Overview
  • 7.3.3 Takeda Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Takeda Albumin (as Excipient) Product Offerings
  • 7.3.5 Takeda Recent Development
• 7.4 Octapharma
  • 7.4.1 Octapharma Company Information
  • 7.4.2 Octapharma Introduction and Business Overview
  • 7.4.3 Octapharma Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Octapharma Albumin (as Excipient) Product Offerings
  • 7.4.5 Octapharma Recent Development
• 7.5 Hualan Bio
  • 7.5.1 Hualan Bio Company Information
  • 7.5.2 Hualan Bio Introduction and Business Overview
  • 7.5.3 Hualan Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Hualan Bio Albumin (as Excipient) Product Offerings
  • 7.5.5 Hualan Bio Recent Development
• 7.6 CBPO
  • 7.6.1 CBPO Company Information
  • 7.6.2 CBPO Introduction and Business Overview
  • 7.6.3 CBPO Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 CBPO Albumin (as Excipient) Product Offerings
  • 7.6.5 CBPO Recent Development
• 7.7 Shanghai RAAS
  • 7.7.1 Shanghai RAAS Company Information
  • 7.7.2 Shanghai RAAS Introduction and Business Overview
  • 7.7.3 Shanghai RAAS Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Shanghai RAAS Albumin (as Excipient) Product Offerings
  • 7.7.5 Shanghai RAAS Recent Development
• 7.8 Kedrion
  • 7.8.1 Kedrion Company Information
  • 7.8.2 Kedrion Introduction and Business Overview
  • 7.8.3 Kedrion Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Kedrion Albumin (as Excipient) Product Offerings
  • 7.8.5 Kedrion Recent Development
• 7.9 LFB Group
  • 7.9.1 LFB Group Company Information
  • 7.9.2 LFB Group Introduction and Business Overview
  • 7.9.3 LFB Group Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 LFB Group Albumin (as Excipient) Product Offerings
  • 7.9.5 LFB Group Recent Development
• 7.10 Tiantan Bio
  • 7.10.1 Tiantan Bio Company Information
  • 7.10.2 Tiantan Bio Introduction and Business Overview
  • 7.10.3 Tiantan Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Tiantan Bio Albumin (as Excipient) Product Offerings
  • 7.10.5 Tiantan Bio Recent Development
• 7.11 Pailin Bio
  • 7.11.1 Pailin Bio Company Information
  • 7.11.2 Pailin Bio Introduction and Business Overview
  • 7.11.3 Pailin Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Pailin Bio Albumin (as Excipient) Product Offerings
  • 7.11.5 Pailin Bio Recent Development
• 7.12 Boya Bio
  • 7.12.1 Boya Bio Company Information
  • 7.12.2 Boya Bio Introduction and Business Overview
  • 7.12.3 Boya Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Boya Bio Albumin (as Excipient) Product Offerings
  • 7.12.5 Boya Bio Recent Development
• 7.13 Yuanda Shuyang
  • 7.13.1 Yuanda Shuyang Company Information
  • 7.13.2 Yuanda Shuyang Introduction and Business Overview
  • 7.13.3 Yuanda Shuyang Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Yuanda Shuyang Albumin (as Excipient) Product Offerings
  • 7.13.5 Yuanda Shuyang Recent Development
• 7.14 Weiguang Bio
  • 7.14.1 Weiguang Bio Company Information
  • 7.14.2 Weiguang Bio Introduction and Business Overview
  • 7.14.3 Weiguang Bio Albumin (as Excipient) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Weiguang Bio Albumin (as Excipient) Product Offerings
  • 7.14.5 Weiguang Bio Recent Development

8 Industry Chain Analysis

• 8.1 Albumin (as Excipient) Industrial Chain
• 8.2 Albumin (as Excipient) Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Albumin (as Excipient) Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Albumin (as Excipient) Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer